MPLT
MapLight Therapeutics, Inc. Common Stock
NASDAQ: MPLT · HEALTHCARE · BIOTECHNOLOGY
$30.70
-3.67% today
Updated 2026-05-01
Market cap
$1.30B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-18.56
Dividend yield
—
52W range
$12 – $33
Volume
0.3M
MapLight Therapeutics, Inc. Common Stock (MPLT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $574000.00 | $556000.00 | $701000.00 | $578000.00 |
| Gross profit | $-574000.00 | $-556000.00 | $-701000.00 | $-578000.00 |
| Gross margin | — | — | — | — |
| R&D | $26.57M | $49.12M | $67.82M | $137.77M |
| SG&A | $4.10M | $7.61M | $14.42M | $30.73M |
| Operating income | $-31.25M | $-57.28M | $-82.95M | $-169.08M |
| Operating margin | — | — | — | — |
| EBITDA | $-29.44M | $-55.15M | $-76.88M | $-168.50M |
| EBITDA margin | — | — | — | — |
| EBIT | $-30.02M | $-55.71M | $-77.58M | $-169.08M |
| Interest expense | — | — | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-30.02M | $-55.71M | $-77.58M | $-161.15M |
| Net income growth (YoY) | — | -85.6% | -39.3% | -107.7% |
| Profit margin | — | — | — | — |